TriangleHEALTH PROFESSIONAL · SOURCE READING
Posterior fossa B ependymoma (PF-EPN-B)
Source: Childhood Cancer Genomics (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 30, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
The PF-EPN-B subgroup is less common than the PF-EPN-A subgroup, representing 15% to 20% of all posterior fossa ependymomas in children. PF-EPN-B is characterized by the following:
Presentation primarily in adolescents and young adults (median age, 30 years).[166,171]
Low rates of variants that affect protein structure (approximately five per genome), with no recurring variants.[168]
Source links and citations
Numerous cytogenetic abnormalities, primarily involving the gain/loss of whole chromosomes.[166,168]
Retained H3 K27 trimethylation.[175]
Source links and citations
1q gain and 6q loss occur in PF-EPN-B but have not been reported as prognostic in this subgroup (unlike in PF-EPN-A).[180]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice